Background: Mammary hyperplasia is one of the most common benign breast disorders. Although traditional
Introduction
Mammary hyperplasia, whose prevalence increases annually, is one of the leading benign breast disorders among women of reproductive age (Ferrara, 2011) . Women with mammary hyperplasia are at increased risk for developing breast cancer (Silvera et al., 2008) . In some areas of China, the incidence of mammary hyperplasia is almost close to 30% (Mo, 2011) , constituting a severe threat to women's physical/mental health and life quality.
Traditional Chinese medicine has a vast experience in treating mammary hyperplasia (Hu and Li, 2015) , but the underneath mechanisms are not clear yet, which limiting its application worldwide. Suitable animal models are versatile experimental system to unravel these mechanic questions.
Rodents are commonly used in the field of breast research, because the mammary gland development of these animals closely resembles that of the human breast (Hovey et al., 2004 ; Macias, H. and Hinck, L., 2012). A rat model of mammary hyperplasia has been reported (Chen et al., 2015) , whereas how to set up a mouse model is still not clear.
The rat model, in certain ways, is easier to use and is very reproducible. However, the mouse model has the advantage of manipulating genetic mutations within the mammary epithelial cell. Thus, the suspected mechanism of the traditional medicine can be effectively investigated in the mice with specific gene mutations. In addition, mice require less consumption of food and drug, and the corresponding research cost is also lower. Therefore, it is necessary to establish a mammary hyperplasia model in mice.
Estrogen and progesterone are pivotal hormones for mammary ductal elongation and branching during puberty 250 days, they were still noticeably higher than those in vehicle-treated group ( Figure 1A ). These confirmed that intragastric administration of estradiol valerate and progesterone could increase estradiol and progesterone level abnormally in the serum of mice and this increase could be maintained for a month.
Next, we performed whole mount staining to check if the increased level of estradiol and progesterone could affect the morphology of mammary glands. Compared with vehicle-treated glands, hormone-treated mammary glands displayed an evident hyperplasia characterized by an increased number of branches, side-branches and terminal end buds and an appearance of alveolar structures as well ( Figure 1B) . To quantify the morphological changes, the numbers of the secondary and tertiary branch points of mammary glands were counted under the microscope. As shown in Figure 1C , hormone treatment resulted in a notable increase in the number of branch points (p<0.05). Further, HE staining showed that hormone-treated glands had an extended lumen with more liquid, the ducts were composed of multiple layers of epithelial cells, and the alveolar buds were fully formed compared to vehicle-treated glands ( Figure   1D ). These morphological changes were not recovered after 30 days of hormone withdrawal ( Figure 1B and 1D) . Thus, intragastric administration of estradiol valerate tablets and progesterone capsules can induce mammary hyperplasia in mice. In mammary epithelial cells, estradiol acts through it receptor ERα, and progesterone functions through PR (Arendt et al., 2015) . We then checked the expression of ERα and PR to determine if they were involved in the morphological changes observed above. We found that the expression levels of ERα and PR were increased in mammary gland due to hormone treatment (Figure 2) , which is in line with Gupta's study (Gupta et al., 2015) . Gupta and her colleagues have proven that the expression of ER and PR parallels the intensity of hyperplasia in benign breast diseases. PR has two isoforms: PRA and PRB. PRA overexpressed in mice induces ductal hyperplasia (Shyamala et al., 1998) , whereas mice lacking PRB, but not PRA, exhibit marked defects in branching and alveologenesis (Mulac-Jericevic et al., 2003) , suggesting that PRB is the predominant isoform required for mammary gland development and expansion. We detected that both PRA and PRB were weakly expressed in vehicle-treated gland at the similar level ( Figure 2B ). They were upregulated after hormone treatment and the ratio of PRB: PRA was also increased ( Figure 2B ). The imbalanced PRA and PRB expression is linked to high risk of breast cancer in women (Mote et al., 2002) . Therefore, the mammary hyperplasia induced by estradiol valerate and progesterone shows the similar pattern of ER and PR to that detected in women with breast hyperplasia.
In conclusion, we successfully established a mammary hyperplasia model in mice by intragastric administration of estradiol valerate and progesterone. This model will facilitate research pertaining to the mechanism study of traditional medicine.
